Compare AbCellera Biologics Inc (ABCL) vs First Solar, Inc. (FSLR) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

First Solar (FSLR) trades at $227.72, up 1.4% with a bearish technical signal despite strong fundamentals. The company shows robust financial performance with $5.22B revenue, 30.73% net margin, and positive cash flow trends. Recent earnings beat expectations in Q1 2026 but missed in previous quarters. Multiple class action lawsuits create significant headwinds, though Deutsche Bank recently upgraded the stock citing valuation discount.

The stock presents a valuation opportunity with P/E of 15.06 below industry averages, but legal risks and technical weakness suggest cautious optimism. Analyst consensus price target of $272.20 implies 19.5% upside potential, though investors must weigh strong profitability against ongoing litigation concerns and bearish technical indicators.